Every 10-Q that TherapeuticsMD, Inc. (TXMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TXMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TXMD filings page.
TherapeuticsMD, Inc. (TXMD) now operates as a pharmaceutical royalty company, collecting royalties on women’s health products such as IMVEXXY, BIJUVA, ANNOVERA and prenatal vitamins licensed to Mayne Pharma and others. For the six months ended June 30, 2026, license revenue from these agreements was $1.6 million, up from $1.3 million in 2025, and the company reported net income of $0.3 million versus a prior-year loss.
Operating expenses declined modestly to $3.1 million, helped by lower professional fees and smaller patent write‑offs, while other income of $1.8 million (including sublease income and interest) supported profitability. Cash and cash equivalents were $9.2 million and total assets $37.5 million, against total liabilities of $10.4 million, leaving stockholders’ equity at $27.1 million as of June 30, 2026.
The company discloses that its primary revenue comes from a concentrated set of licensees, including Mayne Pharma, Theramex and Knight, with royalty receivables totaling $16.0 million current and long term. Management states that uncertainties around royalty performance, working capital true‑ups and related disputes with Mayne Pharma, access to future financing and broader capital market conditions raise substantial doubt about its ability to continue as a going concern over the next 12 months. No adjustments have been made to the financial statements for this uncertainty.
TherapeuticsMD has transformed into a pharmaceutical royalty company after the December 30, 2022 Mayne Transaction that generated $140.0 million in cash plus approximately $12.1 million for net working capital and $1.0 million in prepaid royalties. Under the Mayne License Agreement Mayne Pharma pays royalties of 8.0% on the first $80.0 million of U.S. annual net sales and 7.5% thereafter, with a $3.0 million minimum annual royalty for 12 years (adjusted 3% annually) and a 20-year royalty term.
For the quarter ended June 30, 2025 TherapeuticsMD reported $952 thousand of license revenue (up from $234 thousand a year earlier) and net income of $551 thousand or $0.05 per share. Cash totaled $6.069 million and royalty receivables were $3.743 million (short-term) and $14.840 million (long-term). The company discloses concentration (100% of license revenue from Mayne, Theramex and Knight), ongoing disputes with Mayne Pharma over net working capital and indemnification that gave rise to litigation, and states substantial doubt about its ability to continue as a going concern for the next twelve months.